University of Oxford Confidence in Concept – Round 7
Lead Research Organisation:
University of Oxford
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept (CIC) scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions to flexibly support a portfolio of early stage translational research projects. CIC is designed to accelerate the transition from discovery research to viable translational projects by supporting preliminary studies to establish proof-of-concept so that the approach will then become competitive for more substantial translational funding
Organisations
People |
ORCID iD |
Matthew Wood (Principal Investigator) |
Publications
O'Neil A
(2023)
A GMP Protocol for the Manufacture of Tregs for Clinical Application.
in Methods in molecular biology (Clifton, N.J.)
Peddle CF
(2020)
CRISPR Interference-Potential Application in Retinal Disease.
in International journal of molecular sciences
Quinn J
(2021)
Genome-Editing Strategies for Treating Human Retinal Degenerations.
in Human gene therapy
Stark HL
(2021)
Immune Monitoring for Advanced Cell Therapy Trials in Transplantation: Which Assays and When?
in Frontiers in immunology
Staurenghi F
(2022)
Minicircle Delivery to the Neural Retina as a Gene Therapy Approach.
in International journal of molecular sciences
Stevanovic M
(2022)
CRISPR Systems Suitable for Single AAV Vector Delivery.
in Current gene therapy
Wing PAC
(2022)
Hypoxia inducible factors regulate infectious SARS-CoV-2, epithelial damage and respiratory symptoms in a hamster COVID-19 model.
in PLoS pathogens
Zamora M
(2022)
DyNeuMo Mk-1: Design and pilot validation of an investigational motion-adaptive neurostimulator with integrated chronotherapy
in Experimental Neurology
Description | BRAINSTATE - To develop the DyNeuMo device for use in minimally conscious state (Alex Green) |
Amount | £697,119 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 08/2022 |
End | 07/2025 |
Description | Developing CRISPR delivery strategies for the treatment of inherited retinal diseases |
Amount | £60,000 (GBP) |
Organisation | The Royal College of Surgeons of Edinburgh |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 10/2020 |
End | 09/2021 |
Description | ReSHAPE |
Amount | £151,875 (GBP) |
Funding ID | 825392 |
Organisation | European Commission H2020 |
Sector | Public |
Country | Belgium |
Start | 01/2019 |
End | 12/2023 |
Description | Experts in Residence meeting with Astra Zeneca |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Industry/Business |
Results and Impact | The purpose of the session was to discuss the longer term translational implications of the project via the experts in residence scheme. A wealth of information was transmitted to our research team on the validation routes for the project and how to consolidate the engagement and the collaboration prospects on this award. |
Year(s) Of Engagement Activity | 2020 |
Description | Industry engagement activities with Kymab / Sanofi |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Industry/Business |
Results and Impact | The project team has been discussing a collaboration project with Kymab / Sanofi. |
Year(s) Of Engagement Activity | 2020 |
Description | Industry engagement activities with UCB Pharma - (Alison Simmons) |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Industry/Business |
Results and Impact | Discussing potential licensing agreement, pending data from larger sets of efficacy studies and safety/toxicology profiling of our monoclonal antibodies. |
Year(s) Of Engagement Activity | 2021 |